# Kisspeptin and Testosterone: Male HPG Research > Kisspeptin and testosterone: the male HPG-axis data showing kisspeptin-10 raising LH and serum testosterone in healthy men and in type 2 diabetes — every readout cited to its study and route. What the controlled studies actually measured when kisspeptin was given to men — LH first, testosterone downstream — and why tachyphylaxis caps the effect. ## The short version The link between kisspeptin and testosterone is real but indirect. Kisspeptin does not contain testosterone and does not make it directly. Instead it switches on the GnRH neurons in the brain, which tell the pituitary to release LH, and LH is what tells the testes to make testosterone. So when researchers give men kisspeptin, LH moves first and most, and testosterone follows. The numbers are specific and come from healthy male volunteers. Intravenous kisspeptin-10 raised LH from 4.1 to 12.4 IU/L, sped up LH pulses, and at a higher infusion lifted serum testosterone from 16.6 to 24.0 nmol/L [3]. In men with type 2 diabetes and mildly low testosterone, kisspeptin still raised LH and testosterone, suggesting part of their problem starts in the brain [9]. Two honest limits: the gains fade with repeated dosing (tachyphylaxis) [16], and kisspeptin is investigational — not an approved testosterone treatment and not a supplement. No dose on this page is a recommendation. ## How kisspeptin reaches testosterone — the chain, in order Kisspeptin sits at the very top of the male reproductive hormone chain (the HPG axis: hypothalamus → pituitary → gonad). It binds KISS1R on hypothalamic GnRH neurons and makes them fire, releasing GnRH in pulses. GnRH drives the pituitary to release LH (and FSH). LH then stimulates the Leydig cells of the testes to produce testosterone [1]. Every step is the body's own machinery — kisspeptin only flips the first switch. That ordering is why LH is the headline readout in every male study and testosterone is the slower, downstream one. It is also why kisspeptin is not interchangeable with a sex hormone or a GnRH drug: it is the upstream signal, not the hormone and not the next molecule down. The naming history underlines the distinction — the same KISS1 gene was first described as a cancer metastasis suppressor before its reproductive role was understood [13]. ## Does kisspeptin increase testosterone? What was measured in men In healthy men, the answer from controlled studies is yes — within a specific, dose-dependent window. An intravenous kisspeptin-10 bolus produced maximal LH stimulation at 1 µg/kg (LH 4.1 → 12.4 IU/L at 30 minutes); continuous infusion at 1.5 µg/kg/h raised mean LH from 5.2 to 14.1 IU/L and increased LH pulse frequency from 0.7 to 1.0 pulses/h; and a higher 4 µg/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L [3]. An earlier kisspeptin-54 infusion likewise raised LH (smaller rises in FSH and testosterone) and characterized the 27.6-minute half-life of that isoform [8]. These are acute readouts in supervised research, reported by route and population — not a protocol for raising testosterone in anyone. The literature measures the response; it does not prescribe it. ## Kisspeptin, testosterone and central hypogonadism The most clinically suggestive male finding comes from type 2 diabetes. In men with type 2 diabetes and mild biochemical hypogonadism, kisspeptin-10 stimulated serum testosterone and LH secretion — evidence that part of their low testosterone originates centrally, in reduced kisspeptin signaling at the hypothalamus, rather than solely in the testes [9]. That makes kisspeptin a research probe of *where* a man's hypogonadism begins, and a candidate mechanism worth studying — not an established therapy. The questions men most often ask — whether kisspeptin could restore endogenous testosterone in those on testosterone-replacement therapy, or serve in recovery after anabolic-steroid use — are exactly that: open research questions. The controlled data establishes that kisspeptin can raise LH and testosterone acutely in healthy men [3]; it has not been tested as a restoration protocol in either of those populations, and nothing here should be read as one. ## The ceiling: tachyphylaxis caps the testosterone response Any discussion of kisspeptin and testosterone has to end on its hard limit. The LH-and-testosterone response is not something continuous dosing can hold open. Twice-daily subcutaneous kisspeptin-54 caused the acute LH increment to fall from about 24 IU/L on day 1 to roughly 2.5 IU/L by the 14th injection day [16], and high-dose continuous IV infusion desensitized the axis during the infusion [4]. Because LH drives testosterone, a fading LH response means a fading testosterone response. The data points toward well-spaced or pulsatile exposure preserving the effect better than continuous dosing — a statement about receptor biology, not a regimen. Combined with kisspeptin's investigational, unapproved status [7], this is why the male-testosterone story remains a research finding rather than a treatment. --- A data-forward monograph of the kisspeptin literature — every endocrine readout logged to its study, population and route, with the tachyphylaxis ceiling and the investigational status kept in plain view; no clinic behind the page and nothing here dosed, prescribed, or sold.